Bio-Path Holdings, Inc. :BPTH-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016

Bio-Path Holdings, Inc. reports financial results for the quarter ended September 30, 2016.


  • Summary numbers: Revenues of USD 0 million, Net Earnings of USD -1.57 million.
  • The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.
  • BPTH-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • Cash and Cash equivalents were up this period to 11.30 million compared to 9.85 million in the same period last year.
  • We consider the company to have a Quick & Able profile as it currently does not have any debt. In comparison, the median level of debt as percent of enterprise value for its peer group is currently 10.87%.
  • Of the 10 chosen peers for the company, only 8 of the stocks have an outstanding debt balance. Companies with no debt include SGEN-US and STML-US.
  • Net income of -1.57 million this period compared to a net income of -1.94 million last period. This is a growth of 19.16% over the previous period. In comparison, the peer group grew at -1.87%

Access our Ratings and Scores for Bio-Path Holdings, Inc.

Earnings Growth YOY %
Cash & ST Investments %

Access our Ratings and Scores for Bio-Path Holdings, Inc.

Company Profile

Bio-Path Holdings, Inc. is a clinical stage biotechnology company, which focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. Bio-Path Holdings was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Maria Tari in May 10, 2007 and is headquartered in Bellaire, TX.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of BPTH-US.